Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole

Inclusion Criteria: * Participants of both sexes; * Age greater than or equal to 18 and less than or equal to 50 years; * Participant diagnosed with type dyspepsia epigastric pain carriers of Helicobacter pylori infection, according to the classification of ROME III; * Ability to understand and consent to participate in this clinical study, manifested by reading, understanding and signing of the Informed Consent (IC). Exclusion Criteria: * Any finding of clinical observation (clinical evaluation / physical) that is interpreted by the investigator as a medical risk to participate in the clinical trial; * Any laboratory examination found that the investigator doctor considers a risk to the research participant for their participation in the clinical trial; * Known hypersensitivity to the drug components used during the study; * Women in pregnancy or breastfeeding period; * Women in reproductive age who do not agree to use acceptable methods of contraception (oral contraceptives, injectable contraceptive, IUD, hormonal implants, barrier methods, abstinence, hormonal patch and tubal ligation); except surgically sterile (bilateral oophorectomy or hysterectomy); * Participating in the research that has participated in clinical trial protocols in the last twelve (12) months (CNS Resolution 251 of August 7, 1997, Part III, sub-item J), unless the investigator considers that there may be direct benefit to it; * Party that has some kinship to the second degree or bond with employees or employees of Sponsor and Research Center; * Patients with predominant symptoms of reflux or irritable bowel syndrome, warning symptoms, peptic ulcer history or previous surgery in the upper segment of the gastrointestinal tract; * Patients with prior treatment history of eradication of Helicobacter pylori; * Patients with kidney, liver or heart failure; * Patients with past or current history of alcohol abuse; * Patients with a history of use of antibiotics or bismuth in the 4 weeks prior to study entry, PPIs or H2 blockers, NSAIDs or aspirin in the last two weeks; * Patients whose endoscopy show changes except hyperemic gastritis, erosive gastritis den considering the maximum of 5 erosions in this location or hiatal hernia; * Patients whose ultrasonography show hepato-biliopancreatic changes except steatosis.